Eberbach, Germany—A new randomized controlled trial published inNutrients has shown the benefits of Gelita’s Fortigel in reducing intensity of knee joint pain in healthy men and women, according to a press release.

The study, performed by researchers at the University of Freiburg, investigated Fortigel, made with specific Bioactive Collagen Peptides intended to help maintain joint mobility and minimize joint discomfort. It involved 180 men and women who reported joint discomfort with physical activity. The participants were given either 5g Fortigel daily or a placebo for 12 weeks.

The study found that supplementation with Fortigel resulted in statistically significant reduction in pain during activity compared with the placebo, as assessed by both the study participants and the physician.

Related: Gelita Presents 2019 Corporate Social Responsibility Report OptiMSM to Feature Informed-Ingredient Logo Studies Examine Effects of Curcumin on OA, Oral Mucositis

The researchers concluded: “The oral intake of bioactive collagen peptides used in the current investigation led to a statistically significant reduction of activity-related joint pain in young active adults suffering from knee joint discomfort.”

Dr. Stephan Hausmanns, VP Health & Nutrition at Gelita, stated in the press release: “Fortigel is the most clinically studied Bioactive Collagen Peptides, for 30 years. Over 20 studies, involving more than 2,500 participants, contributed to develop Fortigel and prove the product’s positive effects on joint health. So far, no other collagen peptide solution on the market has been able to offer an alternative to Fortigel backed by science.”